Update on optimal use of omalizumab in management of asthma

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelaia, Girolamo, Gallelli, Luca, Renda, Teresa, Romeo, Pasquale, Busceti, Maria Teresa, Grembiale, Rosa Daniela, Maselli, Rosario, Marsico, Serafino Antonio, Vatrella, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140296/
https://www.ncbi.nlm.nih.gov/pubmed/21792319
http://dx.doi.org/10.2147/JAA.S14520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140296/
https://www.ncbi.nlm.nih.gov/pubmed/21792319
http://dx.doi.org/10.2147/JAA.S14520

Ejemplares similares